⚡ Top Events Today
Revolution's pancreatic cancer drug nearly doubles survival in Phase 3
The drug nearly doubled survival in a pivotal trial, prompting an analyst to call the results a 'game changer' for the difficult-to-treat tumor.
Replimune receives second CRL for cancer therapy, leading to layoffs
Received a second Complete Response Letter (CRL) from the FDA for its cancer therapy, leading to multiple rounds of layoffs.
Travere's Filspari wins expanded approval for rare kidney disease
Received FDA approval to reduce proteinuria in patients with FSGS, expanding its total estimated U.S. market opportunity to $3 billion.
Lilly's Jaypirca succeeds in fourth Phase 3 CLL trial
Achieved its fourth positive Phase 3 readout in CLL, demonstrating efficacy in a fixed-duration treatment setting, an industry first for the drug in this indication.
Ideaya and Servier's eye cancer drug meets primary endpoint
The drug met its primary endpoint in a pivotal Phase 2/3 trial, paving the way for a filing for accelerated FDA approval in H2 2026.
📁 All Events (13747 stories)
Travere's Filspari received a new U.S. approval for a rare kidney disease, adding to its initial 2023 approval for another rare kidney indication. This expands the drug's estimated U.S. market opportunity to $3 billion.
Travere's Filspari received a new U.S. approval for a rare kidney disease, adding to its initial 2023 approval for another rare kidney indication. This expands the drug's estimated U.S. market opportunity to $3 billion.
An opinion piece discusses the lack of access for an adult patient to a recently approved breakthrough drug for a rare disease. The author points out that adults are frequently overlooked in rare disease clinical trials and advocacy efforts.
An opinion piece discusses the lack of access for an adult patient to a recently approved breakthrough drug for a rare disease. The author points out that adults are frequently overlooked in rare disease clinical trials and advocacy efforts.
Travere Therapeutics has gained FDA approval for Filspari (sparsentan) to reduce proteinuria. The approval is for patients aged eight years and over with FSGS without nephrotic syndrome.
Travere Therapeutics has gained FDA approval for Filspari (sparsentan) to reduce proteinuria. The approval is for patients aged eight years and over with FSGS without nephrotic syndrome.
Apotex Corp., in partnership with Orbicular Pharmaceutical Technologies and Gland Pharma, announced FDA approval for the first generic Infuvite® Adult Injection. This approval includes 180-day Competitive Generic Therapy (CGT) exclusivity for the Pharmacy bulk package.
Apotex Corp., in partnership with Orbicular Pharmaceutical Technologies and Gland Pharma, announced FDA approval for the first generic Infuvite® Adult Injection. This approval includes 180-day Competitive Generic Therapy (CGT) exclusivity for the Pharmacy bulk package.
Replimune received a second complete response letter (CRL) for its cancer therapy, leading to multiple rounds of layoffs. This regulatory rejection raises existential questions about the company's future unless it can find a path forward.
Replimune received a second complete response letter (CRL) for its cancer therapy, leading to multiple rounds of layoffs. This regulatory rejection raises existential questions about the company's future unless it can find a path forward.
Ideaya Biosciences and Servier's eye cancer drug candidate met its primary endpoint in a phase 2/3 trial. This positive result paves the way for a filing for accelerated FDA approval in the second half of the year.
Ideaya Biosciences and Servier's eye cancer drug candidate met its primary endpoint in a phase 2/3 trial. This positive result paves the way for a filing for accelerated FDA approval in the second half of the year.
Revolution announced positive Phase 3 results for its pancreatic cancer drug, which nearly doubled survival in a key trial. An analyst described the results as a "game changer" for the difficult-to-treat tumor.
Revolution announced positive Phase 3 results for its pancreatic cancer drug, which nearly doubled survival in a key trial. An analyst described the results as a "game changer" for the difficult-to-treat tumor.
Eli Lilly's BTK inhibitor Jaypirca achieved its fourth positive phase 3 readout in chronic lymphocytic leukemia (CLL). This trial demonstrated fixed-duration power, marking an industry first for the drug in this indication.
Eli Lilly's BTK inhibitor Jaypirca achieved its fourth positive phase 3 readout in chronic lymphocytic leukemia (CLL). This trial demonstrated fixed-duration power, marking an industry first for the drug in this indication.
Artivion, an Atlanta-based medtech, received pre-market approval (PMA) from the FDA for its aortic stent graft system. This regulatory clearance also triggered a buyout option for Endospan.
Artivion, an Atlanta-based medtech, received pre-market approval (PMA) from the FDA for its aortic stent graft system. This regulatory clearance also triggered a buyout option for Endospan.
The FDA has approved a GLP-1 pill for the treatment of obesity. This approval was reported by Nature Reviews Drug Discovery on April 2, 2026.
The FDA has approved a GLP-1 pill for the treatment of obesity. This approval was reported by Nature Reviews Drug Discovery on April 2, 2026.
Preliminary results from the ADARNAT pilot phase, a phase 3 multicentre trial, suggest that axillary radiotherapy (ART) without lymphadenectomy might safely replace axillary lymphadenectomy (ALND) in breast cancer patients with limited node disease. The trial, conducted across 23 Spanish hospitals, randomized 272 patients.
Preliminary results from the ADARNAT pilot phase, a phase 3 multicentre trial, suggest that axillary radiotherapy (ART) without lymphadenectomy might safely replace axillary lymphadenectomy (ALND) in breast cancer patients with limited node disease. The trial, conducted across 23 Spanish hospitals,
The US Food and Drug Administration (FDA) recently approved a first-of-its-kind device. This device is intended for adult patients with locally advanced pancreatic cancer.
The US Food and Drug Administration (FDA) recently approved a first-of-its-kind device. This device is intended for adult patients with locally advanced pancreatic cancer.
The US Food and Drug Administration (FDA) approved icotrokinra, a first-in-class interleukin-23 receptor antagonist. It is indicated for the treatment of moderate to severe plaque psoriasis in patients aged 12 years or older.
The US Food and Drug Administration (FDA) approved icotrokinra, a first-in-class interleukin-23 receptor antagonist. It is indicated for the treatment of moderate to severe plaque psoriasis in patients aged 12 years or older.
A randomized trial demonstrated that iFR-guided coronary artery bypass grafting (CABG) significantly improved LIMA-to-LAD artery graft patency (80.5% vs. 56.8%) and saphenous vein graft patency (90.2% vs. 70.3%) at 36 months compared to angiography-guided CABG. Major adverse cardiac and cerebrovascular events were similar between the groups.
A randomized trial demonstrated that iFR-guided coronary artery bypass grafting (CABG) significantly improved LIMA-to-LAD artery graft patency (80.5% vs. 56.8%) and saphenous vein graft patency (90.2% vs. 70.3%) at 36 months compared to angiography-guided CABG. Major adverse cardiac and cerebrovascu
Gilead Sciences has terminated one of its midstage HIV trials. This action follows the FDA's decision last June to place two of Gilead's next-gen HIV drugs on clinical hold, which remains intact.
Gilead Sciences has terminated one of its midstage HIV trials. This action follows the FDA's decision last June to place two of Gilead's next-gen HIV drugs on clinical hold, which remains intact.
Novo Nordisk is laying off approximately 400 employees at its Bloomington, IN factory. This decision follows FDA rejections of drugs from three different companies that had contracted with the facility, citing manufacturing issues.
Novo Nordisk is laying off approximately 400 employees at its Bloomington, IN factory. This decision follows FDA rejections of drugs from three different companies that had contracted with the facility, citing manufacturing issues.
The U.S. Food and Drug Administration (FDA) has approved Foundayo (orforglipron). This approval is the fifth under the Commissioner's National Priority Voucher (CNPV) pilot program.
The U.S. Food and Drug Administration (FDA) has approved Foundayo (orforglipron). This approval is the fifth under the Commissioner's National Priority Voucher (CNPV) pilot program.
The FDA has approved Lilly's Foundayo (orforglipron), a GLP-1 pill for weight loss. It is notable for being the only GLP-1 pill that can be taken any time of day without food or water restrictions. In the ATTAIN-1 clinical trial, adults on the highest dose lost an average of 27 pounds.
The FDA has approved Lilly's Foundayo (orforglipron), a GLP-1 pill for weight loss. It is notable for being the only GLP-1 pill that can be taken any time of day without food or water restrictions. In the ATTAIN-1 clinical trial, adults on the highest dose lost an average of 27 pounds. | Endpoints:
The ImmunoSep randomized clinical trial (RCT) assessed precision immunotherapy in patients with sepsis. The trial demonstrated that precision immunotherapy was associated with improved organ dysfunction by day 9 compared with placebo.
The ImmunoSep randomized clinical trial (RCT) assessed precision immunotherapy in patients with sepsis. The trial demonstrated that precision immunotherapy was associated with improved organ dysfunction by day 9 compared with placebo. | Endpoints: Organ Dysfunction by Day 9: improved vs placebo